Development, production and testing of novel glycoconjugate pig vaccines

Lead Research Organisation: London Sch of Hygiene and Trop Medicine
Department Name: Department of Pathogen Molecular Biology

Abstract

Healthily maintained livestock are essential for economic and societal prosperity. We propose to exploit ground-breaking technology to produce low cost glycoconjugate vaccines to protect against three major pig diseases (porcine pleuropneumonia, Glässer's disease and S. suis-induced meningitis), where current vaccines are unsatisfactory. We have developed technology to generate cloned glycoconjugates in E. coli cells that act as mini factories to produce an inexhaustible and renewal supply of pure vaccine. Due to production costs, conventional chemically synthesised glycoconjugate vaccines have not been used for animals, but have an excellent track record in humans, where over a billion doses have been used. Through the LSHTM business development office and industrial collaborators we will develop, produce and test new vaccines against the three major pig respiratory diseases. A new company, ArcVax, will be spun-out to further develop the technology and commercialise vaccine product.
 
Description Institutional Translation Partnership Awards 'London School of Hygiene & Tropical Medicine'
Amount £800,000 (GBP)
Funding ID 214227/Z/18/Z 
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2019 
End 03/2021
 
Description Hilleman Labs 
Organisation MSD Wellcome Trust Hilleman Laboratories
Country India 
Sector Charity/Non Profit 
PI Contribution Intellectual contribution and vaccine development and production.
Collaborator Contribution Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Description Merck MSD 
Organisation Merck
Country Germany 
Sector Private 
PI Contribution Collaboration on vaccine development
Collaborator Contribution Intellectual contribution and vaccine development and production
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Description huvepharma 
Organisation Huvepharma
Country Bulgaria 
Sector Private 
PI Contribution Intellectual contribution, vaccine development and production.
Collaborator Contribution Intellectual contribution, vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020